Jbs N.V.

Business Model and Scope

JBS buys animals and agricultural inputs, processes meat and prepared foods, and distributes branded and commodity products. Its seven reportable segments span Brazil, Seara, Beef North America, Pork USA, Pilgrim's Pride, Australia and miscellaneous operations. Farmers and feed suppliers provide livestock and inputs; retailers, food-service operators, distributors and industrial customers buy products; consumers are usually end users rather than JBS's direct payer.

The economic needs are reliable protein supply, food safety, product specification, convenience and logistics. JBS sits between fragmented livestock production and concentrated retail/food-service channels. It monetizes carcass yield, by-products, processing, brands, geographic balancing and cold-chain distribution; cattle, poultry and pork cycles produce materially different margins.

Customers and Purchasing Decisions

Customers can buy from Tyson, Cargill, Marfrig/BRF, WH Group, regional processors, private-label suppliers or alternative proteins. Purchase criteria include delivered price, consistent volume, quality, food safety, animal welfare, traceability, cut/product mix, service and brand demand. Commodity products can switch quickly; customized prepared foods and audited supply programs require qualification and create higher switching consequences.

Consumer brands can support shelf placement and price, but retailers retain bargaining power and can promote private label. Plant scale and distribution density reduce unit cost, yet animal disease or recalls can reverse brand value quickly. Loyalty is economic only where repeat demand and mix exceed advertising, trade promotion and compliance cost.

Profit Creation and Value Capture

2025 net revenue was $86.184 billion and net income attributable to company shareholders was $2.024 billion. Cash generated by operating activities before interest was $4.046 billion; after about $1.302 billion interest paid and other classifications, reported operating cash was about $2.932 billion. Capital expenditure was $2.099 billion. These results combine unlike protein cycles and should not be treated as one normalized margin.

Revenue depends on animal volumes, live-animal/input prices, wholesale pricing, cut and prepared-food mix, exports, currencies and plant utilization. Unit economics are selling value of meat and by-products less livestock/feed, labor, packaging, freight, conversion loss and plant overhead. High throughput spreads fixed plant and cold-chain cost, while biological supply constraints can raise inputs faster than selling prices.

Inventories and biological assets absorb substantial working capital; supplier finance and trade payables fund part of it. The value chain shifts profit among growers, processors, retailers and consumers across cycles. Incremental returns must therefore use through-cycle cash after maintenance capex, interest, environmental/food-safety cost and working-capital needs, not peak segment EBITDA.

Industry Structure and Capital Cycle

Entry requires inspected plants, livestock access, food-safety systems, logistics, customer approvals and working capital. Scale and export permits are barriers, but commodity pricing limits differentiation. Farmers can withhold or expand supply; large retailers and restaurants can rebid volume; labor and regulators can stop plants. Exit is costly because processing assets are location- and species-specific and remediation obligations persist.

High margins encourage herd/flock expansion and processing capacity; biological lags later create oversupply and margin compression. Drought, feed cost and disease can reverse the cycle. Multi-protein and geographic diversification can offset cycles, but it also raises organizational and legal complexity. Acquisitions near cyclical peaks risk paying for temporary earnings.

Sources and Durability of Competitive Advantage

Potential advantages are procurement scale, plant utilization, global export access, cold-chain density, carcass optimization, branded prepared foods and the ability to redirect product among markets. More volume can improve animal procurement, by-product recovery and freight economics; diversified proteins reduce dependence on one biological cycle.

These mechanisms are durable only conditionally. Competitors can build or acquire plants, customers can dual-source, trade barriers can strand regional capacity, and disease or safety failures can remove export licences. Regulation, labor availability and environmental constraints can raise the cost of scale. Evidence of advantage is stable through-cycle return on capital and cash after legal/remediation cost—not revenue size alone.

Operating System and Strategic Trade-offs

JBS forecasts demand, contracts or buys livestock/feed, schedules plants, performs slaughter/fabrication or prepared-food production, tests safety, manages cold storage, sells across channels and recovers by-products. Market prices and yields feed procurement and product-mix decisions; traceability and quality data feed regulatory and customer assurance.

Large plants lower unit cost but concentrate interruption and recall risk. Vertical integration secures birds/feed and specifications but increases biological and working-capital exposure. Global routing improves realizations but adds currency, sanctions and trade risk. Branded processing can stabilize mix but requires marketing and innovation. Inventory buffers service customers but increase spoilage and price risk. The system works only if compliance and maintenance are treated as production inputs, not discretionary overhead.

Financial Resilience

Cash was $4.565 billion. Loans and financing totaled $21.091 billion: $833 million due within one year, $249 million in years two to three, $794 million in years four to five and $19.214 billion thereafter. Estimated interest payments were $21.305 billion over the contractual lives, including $1.265 billion within one year, reflecting long duration as well as rate/currency assumptions. Lease payments totaled $2.088 billion. Gross leverage increased to 2.39x from 1.89x.

Unused revolving capacity was about $3.526 billion, but it was distributed among legal entities rather than one unrestricted parent pool. The JBS USA/JBS N.V. borrower group is subject to a minimum 3.00x interest-coverage test; PPC's $850 million facility requires 3.50x; Moy Park requires 3.00x coverage and no more than 3.00x leverage. Collateral cures can replace some maintenance tests but then limit availability to collateral and restrict distributions, investments and debt. Cash in subsidiaries, including PPC minorities and regulated/currency jurisdictions, is therefore not perfectly fungible. The new $1 billion commercial-paper program had no issuance at year-end.

A severe case combines cattle-cycle compression, avian disease, a major recall, export closures, 15% revenue decline and frozen refinancing. One-year cash plus operating inflow appears able to cover $833 million principal, $1.265 billion estimated interest, leases and essential capex, but prolonged stress could erode coverage, collateral and revolver access. JBS can reduce discretionary capex, acquisitions and distributions and release working capital; it cannot stop animal care, safety, plant maintenance or debt service. Long maturities add time, while absolute debt, entity restrictions and legal claims limit resilience.

Capital Allocation and Shareholder Outcomes

Capital allocation combines plant investment, acquisitions, debt, dividends, repurchases and minority interests. In 2025 capex of $2.099 billion consumed most post-interest operating cash. Dividends/share-premium distributions were about $1.574 billion and treasury-share purchases about $600 million, while lease payments were $432.5 million. These uses exceeded internally generated cash after capex, increasing dependence on balance-sheet capacity.

The 2025 reorganization fixed the comparable weighted denominator at 1,068,508,877 common shares; prior periods were retrospectively restated. Treasury activity must be separated from that structural conversion: 624.5 million shares entered treasury through restructuring and 590.181 million were transferred out; the company separately bought 41,008,292 shares for $600 million, used 458,984 for awards and recorded another 19,669,712 repurchase-related shares, ending with 94,537,534 treasury shares costing $598.423 million. JBS/Seara executive share-linked compensation is cash-settled, while PPC awards can dilute the subsidiary minority layer. The gross buyback alone therefore does not prove a comparable endpoint contraction; the test is through-cycle cash and net assets per fully attributed share after restructuring, awards, debt and minorities.

Legal and Regulatory Exposure

Food safety, contamination and animal disease are high-probability operating exposures with potentially extreme severity, weeks-to-years duration and only partial reversibility. Recalls, plant suspensions or export bans transmit through destroyed inventory, lost throughput, customer claims and licence damage. Animal-welfare, labor and immigration compliance are recurring medium-to-high probability and high severity; corrective investment can reopen plants, while injury and reputation losses persist.

Antitrust and competition litigation is medium-to-high probability given pending protein-market cases, high severity and multi-year duration; settlements are financially reversible but monitoring and customer distrust can persist. Anti-corruption and governance exposure has lower event probability but high fine, debarment and financing consequences, with low reversibility after a control failure. Environmental, water, waste and climate rules are high-probability, long-duration requirements that transmit through capex, permits and operating limits. Tax, trade, sanctions and export regulation are medium-to-high probability and can abruptly alter regional price realization. The filing's roughly $189 million legal provisions and substantial litigation payments are evidence of exposure, not a ceiling on possible loss.

Conclusion, Uncertainties and Disconfirming Evidence

JBS creates value by converting livestock into specified protein products, optimizing yields and by-products, and using global scale and distribution to match supply with demand. It can retain value through procurement/logistics density, customer qualification, brands and export access. Durability is moderate because biological cycles, commodity pricing and regulation repeatedly redistribute returns. Long maturities, liquidity and diversification support resilience; high absolute debt, working capital and event risk constrain it. Common shareholders receive the benefit only if through-cycle cash after capex, interest, legal cost and dilution exceeds distributions and debt growth.

Counterevidence includes increased leverage, heavy distribution/repurchase cash use, cycle-sensitive margins and recurring antitrust/governance scrutiny. The thesis is invalidated by sustained returns below the cost of capital, repeated safety or compliance closures, loss of major export markets, working-capital/debt service consuming cash through a downcycle, or acquisitions/distributions raising debt faster than durable cash per share. Business quality is separate from valuation; no investment action is stated.